News
5h
Zacks Investment Research on MSNWill Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...
Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...
Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...
The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...
Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results